SLC12A3 and cancer: Our results are in agreement with the findings from Yarmolinsky et al. who investigated antihypertensive drug use and risk of common cancers by evaluating SNPs in ACE, ADRB1, and SLC12A3 in GWAS of SBP to proxy genetic inhibition of the angiotensin-converting enzyme (ACE), β-1 adrenergic receptor (ADRB1), and sodium-chloride symporter (NCC) [13].